References
- Vane J. R., Änggärd E. E., Botting R. M. Regulatory functions of the vascular endothelium. N Engl J Med. 1990; 323: 27–36
- Koyama H., Morii H., Tabata T., Nishzawa Y., Inoue T., Yamaji T. Plasma endothelin levels in patients with uraemia. Lancet 1989; 1: 991–992
- Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572–575
- Eschbach J. W., Abdulhadi M. H., Browne J. K., Delano M. D., Downing M., Egrie J. C., Evans R. W., Friedman E. A., Graber S. E., Haley R., Korbet S., Krantz S. B., Lundin P., Nissenson A. R., Ogden D. A., Paganini E. P., Rader B., Rutsky E. A., Stivelman J., Stone W. J., Teschan P., Van Stone J. C., Van Wyck D. B., Zuckerman K., Adamson J. W. Recombinant human erythropoietin in anemic patients with end stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992–1000
- Sundal E., Kaeser U. Correction of anemia of chronic renal failure with recombinant human erythropoietin. Safety and efficacy of one year's treatment in a European multicenter study of 150 hemodialysis-dependent patients. Nephrol Dial Transplant 1989; 4: 979–987
- Anagnostou A., Lee E. S., Kessimian N., Levinson R., Steiner M. Erythropoietin has mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci 1990; 87: 5978–5982
- Carlini R. G., Dusso A. S., Obialo C. I., Alvarez U. M., Rothstein M. Recombinant human erythropoietin (r-HuEPO) increase endothelin-1 release by endothelial cells. Kidney Int 1993; 43: 1010–1014
- Campese V. M. Management of hypertension in chronic dialysis patients. Dialysis Therapy, A. R. Nissenson, R. N. Fine. Handley & Belfus Inc., Philadelphia 1986; 162–166
- Nolph K. D., Popovich R. P., Moncrief J. W. Theoretical and practical implication of continuous ambulatory peritoneal dialysis. Nephron 1978; 21: 117–122
- Naruse M., Nakamura N., Naruse K., Kubo K., Kato M., Hagiwara H., Sugino N., Demura H. Plasma immunoreactive endothelin levels are increased in hemodialysis patients with hypertension following erythropoietin therapy. Hypertension Res 1992; 15: 11–16
- Takahashi K., Totsune K., Imai Y., Sone M., Nozuki M., Murakami O., Sekino H., Mouri T. Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin. Clin Sci 1993; 84: 47–50
- Carlini R., Obialo C. I., Rothstein M. Intravenous erythropoietin (r-HuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertension 1993; 6: 103–107
- Abraham A. P., Macres M. G. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 1991; 2: 927–936